

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **JOINN LABORATORIES (CHINA) CO., LTD.**

### **北京昭衍新藥研究中心股份有限公司**

*(A joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock code: 6127)**

## **ANNOUNCEMENT ON RECEIPT OF GOVERNMENT GRANTS**

### **I. BASIC INFORMATION ON RECEIPT OF GRANTS**

**NOTICE IS HEREBY GIVEN** that JOINN Laboratories (China) Co., Ltd. (the “**Company**”, together with its subsidiaries, collectively the “**Group**”) has cumulatively received various government grants amounting to RMB28,852,800 from 1 January 2025 up to the date of this announcement (unaudited), of which, revenue-related government grants amounted to RMB14,480,800, representing 19.55% of the audited net profit attributable to equity shareholders of the Company for the latest financial year. The asset-related government grants amounted to RMB14,372,000, representing 0.18% of the audited net assets attributable to the equity shareholders of the Company for the latest financial year.

### **II. TYPE OF SUBSIDY AND IMPACT ON THE COMPANY**

The Company has recognised the aforementioned matters in accordance with the relevant provisions of Chinese Accounting Standards for Business Enterprises No. 16 – Government Grants and classified the types of assistance. The revenue-related government grants mentioned above of RMB14,480,800 has been or will be included in other gains and losses, net, with an estimated impact on consolidated profits for the year ended 2025 of RMB12,429,900 (unaudited). The asset-related government grants of RMB14,372,000 have been recognised as deferred income and will be evenly amortised over the expected useful lives of the related assets from the date of readiness for use. The specific accounting treatment and its impact on the Company’s annual profit will be subject to the results confirmed by the auditor after the annual audit.

**Shareholders and potential investors of the Company are advised to exercise caution when trading in the shares of the Company.**

By order of the Board  
**JOINN Laboratories (China) Co., Ltd.**  
**Feng Yuxia**  
*Chairperson*

Beijing, the PRC  
26 August 2025

*As at the date of this announcement, the board of the Company comprises Ms. Feng Yuxia as the Chairperson and executive Director, Mr. Gao Dapeng, Ms. Sun Yunxia, Ms. Luo Xi and Mr. Gu Jingliang as executive Directors, and Mr. Zhang Fan, Mr. Yang Fuquan, Mr. Yang Changyun and Mr. Ying Fangtian as independent non-executive Directors.*